Loading…
Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective
Abstract Objectives: To determine the cost-effectiveness of omalizumab compared with routine clinical practice in the treatment and control of severe persistent asthma. Methods: Cost-effectiveness analysis using pre- and post-treatment with omalizumab after 10 months of 47 patients diagnosed with un...
Saved in:
| Published in: | The Journal of asthma 2015-03, Vol.52 (2), p.205-210 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c418t-9670cbcea1583e4ec8be1e5dc8c057202f7413da656940d4bdcdfc7f5ec0f2513 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c418t-9670cbcea1583e4ec8be1e5dc8c057202f7413da656940d4bdcdfc7f5ec0f2513 |
| container_end_page | 210 |
| container_issue | 2 |
| container_start_page | 205 |
| container_title | The Journal of asthma |
| container_volume | 52 |
| creator | Levy, Alberto Nahon García a Ruiz, Antonio J. García-Agua Soler, Nuria Sanjuan, María Victoria Hidalgo |
| description | Abstract
Objectives: To determine the cost-effectiveness of omalizumab compared with routine clinical practice in the treatment and control of severe persistent asthma. Methods: Cost-effectiveness analysis using pre- and post-treatment with omalizumab after 10 months of 47 patients diagnosed with uncontrolled severe persistent asthma attended by the Pneumology Service, Hospital Universitario Virgen de la Victoria, Malaga. Effectiveness was assessed by the number of emergency room (ER) visits for exacerbations and quality-adjusted life years (QALY) gained. The costs of treatment with omalizumab and ER visits were analyzed using the National Health System perspective. Results are expressed in cost per QALY gained and cost per ER visit avoided (costs €2012). Results: Exacerbations with ER visits decreased significantly (p |
| doi_str_mv | 10.3109/02770903.2014.941474 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1689310779</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1689310779</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-9670cbcea1583e4ec8be1e5dc8c057202f7413da656940d4bdcdfc7f5ec0f2513</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMo7vrxD0R69NI1adOm8aDI4hcIHtSrIU0nbKRtapKurL_elrqCF08DM8-8MzwInRC8SAnm5zhhDHOcLhJM6IJTQhndQXOSpUlMU5zuovmIxCMzQwfev2M8NHC-j2YJ5TzLczJHb0vrQwxagwpmDS14H1kd2UbW5qtvZBmZNvKwBgdRB84bH6ANkfRh1chx9txJ015EMnIg67g2euK6Ke8I7WlZezj-qYfo9fbmZXkfPz7dPSyvH2NFSRFinjOsSgWSZEUKFFRRAoGsUoXCGUtwohklaSXzLOcUV7SsVKUV0xkorJOMpIfobMrtnP3owQfRGK-grmULtveC5AUfrDHGB5ROqHLWewdadM400m0EwWI0K7ZmxWhWTGaHtdOfC33ZQPW7tFU5AFcTYFptXSM_rasrEeSmtk472Srjx_h_T1z-SVgNRsNKSQfi3fauHQT-_-M3gS-caQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1689310779</pqid></control><display><type>article</type><title>Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Levy, Alberto Nahon ; García a Ruiz, Antonio J. ; García-Agua Soler, Nuria ; Sanjuan, María Victoria Hidalgo</creator><creatorcontrib>Levy, Alberto Nahon ; García a Ruiz, Antonio J. ; García-Agua Soler, Nuria ; Sanjuan, María Victoria Hidalgo</creatorcontrib><description>Abstract
Objectives: To determine the cost-effectiveness of omalizumab compared with routine clinical practice in the treatment and control of severe persistent asthma. Methods: Cost-effectiveness analysis using pre- and post-treatment with omalizumab after 10 months of 47 patients diagnosed with uncontrolled severe persistent asthma attended by the Pneumology Service, Hospital Universitario Virgen de la Victoria, Malaga. Effectiveness was assessed by the number of emergency room (ER) visits for exacerbations and quality-adjusted life years (QALY) gained. The costs of treatment with omalizumab and ER visits were analyzed using the National Health System perspective. Results are expressed in cost per QALY gained and cost per ER visit avoided (costs €2012). Results: Exacerbations with ER visits decreased significantly (p < 0.001) after 10 months of omalizumab treatment compared with the previous 10 months [7.94 (6.52-9.37) vs 0.19 (0.03-0.35)]. Health utilities increased significantly (p < 0.001) during the same period [0.5967 (0.5722-0.6212) vs 0.7566 (0.7232-0.7900)], representing 0.1333 (0.1053-0.1612) QALYs gained (p < 0.001).The mean cost per patient was €1850.78 (1519.46-2182.10) in the 10 months before treatment and €5431.87 (4930.72-5933.02) after 10 months of omalizumab treatment. The incremental cost-effectiveness ratios (ICERs) were €462.08/exacerbation avoided (347.65-606.22) and €26 864.89/QALY gained (21 632.07-33 859.49). Conclusions: Our results confirm that adding omalizumab to the treatment of patients with uncontrolled severe persistent asthma reduces the number of exacerbations with ER visits and increases health-related quality of life after 10 months of treatment and produces ICERs favorable to omalizumab and acceptable from the health system perspective.</description><identifier>ISSN: 0277-0903</identifier><identifier>EISSN: 1532-4303</identifier><identifier>DOI: 10.3109/02770903.2014.941474</identifier><identifier>PMID: 24995661</identifier><language>eng</language><publisher>England: Informa Healthcare USA, Inc</publisher><subject>Adult ; Aged ; Anti-Asthmatic Agents - economics ; Anti-Asthmatic Agents - therapeutic use ; Antibodies, Anti-Idiotypic - economics ; Antibodies, Anti-Idiotypic - therapeutic use ; Antibodies, Monoclonal, Humanized - economics ; Antibodies, Monoclonal, Humanized - therapeutic use ; Asthma ; Asthma - drug therapy ; Cost-Benefit Analysis ; cost-utility ; effectiveness ; Emergency Service, Hospital - economics ; Emergency Service, Hospital - statistics & numerical data ; Female ; healthcare costs ; Humans ; Male ; Middle Aged ; Omalizumab ; Quality of Life ; Quality-Adjusted Life Years ; Respiratory Function Tests ; Severity of Illness Index ; Spain</subject><ispartof>The Journal of asthma, 2015-03, Vol.52 (2), p.205-210</ispartof><rights>2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-9670cbcea1583e4ec8be1e5dc8c057202f7413da656940d4bdcdfc7f5ec0f2513</citedby><cites>FETCH-LOGICAL-c418t-9670cbcea1583e4ec8be1e5dc8c057202f7413da656940d4bdcdfc7f5ec0f2513</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24995661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Levy, Alberto Nahon</creatorcontrib><creatorcontrib>García a Ruiz, Antonio J.</creatorcontrib><creatorcontrib>García-Agua Soler, Nuria</creatorcontrib><creatorcontrib>Sanjuan, María Victoria Hidalgo</creatorcontrib><title>Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective</title><title>The Journal of asthma</title><addtitle>J Asthma</addtitle><description>Abstract
Objectives: To determine the cost-effectiveness of omalizumab compared with routine clinical practice in the treatment and control of severe persistent asthma. Methods: Cost-effectiveness analysis using pre- and post-treatment with omalizumab after 10 months of 47 patients diagnosed with uncontrolled severe persistent asthma attended by the Pneumology Service, Hospital Universitario Virgen de la Victoria, Malaga. Effectiveness was assessed by the number of emergency room (ER) visits for exacerbations and quality-adjusted life years (QALY) gained. The costs of treatment with omalizumab and ER visits were analyzed using the National Health System perspective. Results are expressed in cost per QALY gained and cost per ER visit avoided (costs €2012). Results: Exacerbations with ER visits decreased significantly (p < 0.001) after 10 months of omalizumab treatment compared with the previous 10 months [7.94 (6.52-9.37) vs 0.19 (0.03-0.35)]. Health utilities increased significantly (p < 0.001) during the same period [0.5967 (0.5722-0.6212) vs 0.7566 (0.7232-0.7900)], representing 0.1333 (0.1053-0.1612) QALYs gained (p < 0.001).The mean cost per patient was €1850.78 (1519.46-2182.10) in the 10 months before treatment and €5431.87 (4930.72-5933.02) after 10 months of omalizumab treatment. The incremental cost-effectiveness ratios (ICERs) were €462.08/exacerbation avoided (347.65-606.22) and €26 864.89/QALY gained (21 632.07-33 859.49). Conclusions: Our results confirm that adding omalizumab to the treatment of patients with uncontrolled severe persistent asthma reduces the number of exacerbations with ER visits and increases health-related quality of life after 10 months of treatment and produces ICERs favorable to omalizumab and acceptable from the health system perspective.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Asthmatic Agents - economics</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>Antibodies, Anti-Idiotypic - economics</subject><subject>Antibodies, Anti-Idiotypic - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - economics</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Asthma</subject><subject>Asthma - drug therapy</subject><subject>Cost-Benefit Analysis</subject><subject>cost-utility</subject><subject>effectiveness</subject><subject>Emergency Service, Hospital - economics</subject><subject>Emergency Service, Hospital - statistics & numerical data</subject><subject>Female</subject><subject>healthcare costs</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Omalizumab</subject><subject>Quality of Life</subject><subject>Quality-Adjusted Life Years</subject><subject>Respiratory Function Tests</subject><subject>Severity of Illness Index</subject><subject>Spain</subject><issn>0277-0903</issn><issn>1532-4303</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LxDAQhoMo7vrxD0R69NI1adOm8aDI4hcIHtSrIU0nbKRtapKurL_elrqCF08DM8-8MzwInRC8SAnm5zhhDHOcLhJM6IJTQhndQXOSpUlMU5zuovmIxCMzQwfev2M8NHC-j2YJ5TzLczJHb0vrQwxagwpmDS14H1kd2UbW5qtvZBmZNvKwBgdRB84bH6ANkfRh1chx9txJ015EMnIg67g2euK6Ke8I7WlZezj-qYfo9fbmZXkfPz7dPSyvH2NFSRFinjOsSgWSZEUKFFRRAoGsUoXCGUtwohklaSXzLOcUV7SsVKUV0xkorJOMpIfobMrtnP3owQfRGK-grmULtveC5AUfrDHGB5ROqHLWewdadM400m0EwWI0K7ZmxWhWTGaHtdOfC33ZQPW7tFU5AFcTYFptXSM_rasrEeSmtk472Srjx_h_T1z-SVgNRsNKSQfi3fauHQT-_-M3gS-caQ</recordid><startdate>20150301</startdate><enddate>20150301</enddate><creator>Levy, Alberto Nahon</creator><creator>García a Ruiz, Antonio J.</creator><creator>García-Agua Soler, Nuria</creator><creator>Sanjuan, María Victoria Hidalgo</creator><general>Informa Healthcare USA, Inc</general><general>Informa Healthcare</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150301</creationdate><title>Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective</title><author>Levy, Alberto Nahon ; García a Ruiz, Antonio J. ; García-Agua Soler, Nuria ; Sanjuan, María Victoria Hidalgo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-9670cbcea1583e4ec8be1e5dc8c057202f7413da656940d4bdcdfc7f5ec0f2513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Asthmatic Agents - economics</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>Antibodies, Anti-Idiotypic - economics</topic><topic>Antibodies, Anti-Idiotypic - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - economics</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Asthma</topic><topic>Asthma - drug therapy</topic><topic>Cost-Benefit Analysis</topic><topic>cost-utility</topic><topic>effectiveness</topic><topic>Emergency Service, Hospital - economics</topic><topic>Emergency Service, Hospital - statistics & numerical data</topic><topic>Female</topic><topic>healthcare costs</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Omalizumab</topic><topic>Quality of Life</topic><topic>Quality-Adjusted Life Years</topic><topic>Respiratory Function Tests</topic><topic>Severity of Illness Index</topic><topic>Spain</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Levy, Alberto Nahon</creatorcontrib><creatorcontrib>García a Ruiz, Antonio J.</creatorcontrib><creatorcontrib>García-Agua Soler, Nuria</creatorcontrib><creatorcontrib>Sanjuan, María Victoria Hidalgo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of asthma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Levy, Alberto Nahon</au><au>García a Ruiz, Antonio J.</au><au>García-Agua Soler, Nuria</au><au>Sanjuan, María Victoria Hidalgo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective</atitle><jtitle>The Journal of asthma</jtitle><addtitle>J Asthma</addtitle><date>2015-03-01</date><risdate>2015</risdate><volume>52</volume><issue>2</issue><spage>205</spage><epage>210</epage><pages>205-210</pages><issn>0277-0903</issn><eissn>1532-4303</eissn><abstract>Abstract
Objectives: To determine the cost-effectiveness of omalizumab compared with routine clinical practice in the treatment and control of severe persistent asthma. Methods: Cost-effectiveness analysis using pre- and post-treatment with omalizumab after 10 months of 47 patients diagnosed with uncontrolled severe persistent asthma attended by the Pneumology Service, Hospital Universitario Virgen de la Victoria, Malaga. Effectiveness was assessed by the number of emergency room (ER) visits for exacerbations and quality-adjusted life years (QALY) gained. The costs of treatment with omalizumab and ER visits were analyzed using the National Health System perspective. Results are expressed in cost per QALY gained and cost per ER visit avoided (costs €2012). Results: Exacerbations with ER visits decreased significantly (p < 0.001) after 10 months of omalizumab treatment compared with the previous 10 months [7.94 (6.52-9.37) vs 0.19 (0.03-0.35)]. Health utilities increased significantly (p < 0.001) during the same period [0.5967 (0.5722-0.6212) vs 0.7566 (0.7232-0.7900)], representing 0.1333 (0.1053-0.1612) QALYs gained (p < 0.001).The mean cost per patient was €1850.78 (1519.46-2182.10) in the 10 months before treatment and €5431.87 (4930.72-5933.02) after 10 months of omalizumab treatment. The incremental cost-effectiveness ratios (ICERs) were €462.08/exacerbation avoided (347.65-606.22) and €26 864.89/QALY gained (21 632.07-33 859.49). Conclusions: Our results confirm that adding omalizumab to the treatment of patients with uncontrolled severe persistent asthma reduces the number of exacerbations with ER visits and increases health-related quality of life after 10 months of treatment and produces ICERs favorable to omalizumab and acceptable from the health system perspective.</abstract><cop>England</cop><pub>Informa Healthcare USA, Inc</pub><pmid>24995661</pmid><doi>10.3109/02770903.2014.941474</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-0903 |
| ispartof | The Journal of asthma, 2015-03, Vol.52 (2), p.205-210 |
| issn | 0277-0903 1532-4303 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1689310779 |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | Adult Aged Anti-Asthmatic Agents - economics Anti-Asthmatic Agents - therapeutic use Antibodies, Anti-Idiotypic - economics Antibodies, Anti-Idiotypic - therapeutic use Antibodies, Monoclonal, Humanized - economics Antibodies, Monoclonal, Humanized - therapeutic use Asthma Asthma - drug therapy Cost-Benefit Analysis cost-utility effectiveness Emergency Service, Hospital - economics Emergency Service, Hospital - statistics & numerical data Female healthcare costs Humans Male Middle Aged Omalizumab Quality of Life Quality-Adjusted Life Years Respiratory Function Tests Severity of Illness Index Spain |
| title | Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T19%3A57%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-effectiveness%20of%20omalizumab%20in%20severe%20persistent%20asthma%20in%20Spain:%20a%20real-life%20perspective&rft.jtitle=The%20Journal%20of%20asthma&rft.au=Levy,%20Alberto%20Nahon&rft.date=2015-03-01&rft.volume=52&rft.issue=2&rft.spage=205&rft.epage=210&rft.pages=205-210&rft.issn=0277-0903&rft.eissn=1532-4303&rft_id=info:doi/10.3109/02770903.2014.941474&rft_dat=%3Cproquest_cross%3E1689310779%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c418t-9670cbcea1583e4ec8be1e5dc8c057202f7413da656940d4bdcdfc7f5ec0f2513%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1689310779&rft_id=info:pmid/24995661&rfr_iscdi=true |